


Supplemental Figure 14

Supplemental Figure 14 miR-206 increased hepatic CD4⁺ T cells and reduced Tregs in AKT/Ras mice. (A-B) Levels of hepatic CD4⁺ T cells in FVB/NJ mice injected with pT3-EF1 α (control, $n=6$, 5 w.p.i), AKT/Ras/pT3-CD68p-scramble ($n=6$, 5 w.p.i), or AKT/Ras/pT3-CD68p-miR-206 ($n=6$, 5 w.p.i) (two-way ANOVA test). (C-D) Levels of hepatic CD4⁺ T cells in AKT/Ras ($n=6$, 3 w.p.i), AKT/Ras/MC-CD68p-scramble ($n=6$, 7 w.p.i), and AKT/Ras/MC-CD68p-miR-206 ($n=6$, 7 w.p.i) mice (two-way ANOVA test). (E) Flow cytometry analysis of Tregs (CD4⁺CD25⁺FoxP3⁺) in livers of FVB/NJ mice injected with pT3-EF1 α (control, $n=6$, 5 w.p.i), AKT/Ras/pT3-CD68p-scramble ($n=6$, 5 w.p.i), or AKT/Ras/pT3-CD68p-miR-206 ($n=6$, 5 w.p.i) (two-way ANOVA test). (F) Flow cytometry analysis of hepatic Tregs in AKT/Ras ($n=6$, 3 w.p.i), AKT/Ras/MC-CD68p-scramble ($n=6$, 7 w.p.i), and AKT/Ras/MC-CD68p-miR-206 ($n=6$, 7 w.p.i) mice (two-way ANOVA test). (G) The ratios of CTLs to Tregs in livers of FVB/NJ mice injected with pT3-EF1 α (control, $n=6$, 5 w.p.i), AKT/Ras/pT3-CD68p-scramble ($n=6$, 5 w.p.i), or AKT/Ras/pT3-CD68p-miR-206 ($n=6$, 5 w.p.i) (two-way ANOVA test). (H) The ratios of CTLs to Tregs in livers of AKT/Ras ($n=6$, 3 w.p.i), AKT/Ras/MC-CD68p-scramble ($n=6$, 7 w.p.i), and AKT/Ras/MC-CD68p-miR-206 ($n=6$, 7 w.p.i) mice (two-way ANOVA test). Data represent mean \pm SEM. ** $p < 0.01$, *** $p < 0.001$ and ns: no significance.